View All Cancer Clinical Trials | The University of Kansas Cancer Center

Viewed View Trial

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Study Type: Treatment

Phase: I/II

NCTID: NCT04094961

Principal Investigator: Leyla Shune

Viewed View Trial

Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel

Study Type: Supportive Care

Phase: IV

NCTID: NCT05201781

Principal Investigator: Leyla Shune

Viewed View Trial

Master Screening and Reassessment Protocol MSRP for Tier Advancement in the NCI myeloMATCH Clinical Trials

Study Type: Screening

Phase: N/A

NCTID: NCT05564390

Principal Investigator: Tara Lin

Viewed View Trial

Expanded Access Protocol EaP For Subjects Receiving Idecabtagene vicleucel That Is Nonconforming For commercial Release

Study Type: Treatment

Phase: N/A

NCTID: NCT04771078

Principal Investigator: Nausheen Ahmed

Viewed View Trial

Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma MM

Study Type: Treatment

Phase: I

NCTID: NCT04960579

Principal Investigator: Leyla Shune

Viewed View Trial

A Safety and Efficacy Study of JNJ?68284528 ciltacabtagene autoleucel Out?of?Specification OOS for Commercial Release in Patients with Multiple Myeloma

Study Type: Treatment

Phase: II

NCTID: NCT03548207

Principal Investigator: Leyla Shune

Viewed View Trial

Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma MM Followed by a Phase II Assessment of Response and Safety PRIME

Study Type: Treatment

Phase: I/II

NCTID: NCT03288493

Principal Investigator: Anurag Singh

Viewed View Trial

Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

Study Type: Treatment

Phase: N/A

NCTID: NCT03763370

Principal Investigator: Al-Ola Abdallah

Viewed View Trial

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant ASCENT: A Phase II Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma SMM

Study Type: Treatment

Phase: II

NCTID: NCT03289299

Principal Investigator: Al-Ola Abdallah

Viewed View Trial

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Study Type: Treatment

Phase: III

NCTID: NCT03901963

Principal Investigator: Leyla Shune

Find a Clinical Trial

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel

Master Screening and Reassessment Protocol MSRP for Tier Advancement in the NCI myeloMATCH Clinical Trials

Expanded Access Protocol EaP For Subjects Receiving Idecabtagene vicleucel That Is Nonconforming For commercial Release

Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma MM

A Safety and Efficacy Study of JNJ?68284528 ciltacabtagene autoleucel Out?of?Specification OOS for Commercial Release in Patients with Multiple Myeloma

Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma MM Followed by a Phase II Assessment of Response and Safety PRIME

Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant ASCENT: A Phase II Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma SMM

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Popular Links